Forecasting The Future: 9 Analyst Projections For Tandem Diabetes Care
Across the recent three months, 9 analysts have shared their insights on Tandem Diabetes Care (NASDAQ:TNDM), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 2 | 6 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 2 | 5 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $35.11, a high estimate of $63.00, and a low estimate of $20.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 27.04%.
Deciphering Analyst Ratings: An In-Depth Analysis
In examining recent analyst actions, we gain insights into how financial experts perceive Tandem Diabetes Care. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating |Current Price Target| Prior Price Target | |--------------------|--------------------|---------------|---------------|--------------------|--------------------| |Anthony Petrone |Mizuho |Announces |Neutral | $20.00|- | |Patrick Wood |Morgan Stanley |Lowers |Equal-Weight | $22.00|$45.00 | |Joanne Wuensch |Citigroup |Lowers |Neutral | $24.00|$35.00 | |David Roman |Goldman Sachs |Lowers |Neutral | $24.00|$42.00 | |Larry Biegelsen |Wells Fargo |Lowers |Equal-Weight | $22.00|$38.00 | |Matt Miksic |Barclays |Lowers |Overweight | $53.00|$60.00 | |Shagun Singh |RBC Capital |Lowers |Outperform | $55.00|$65.00 | |Jeff Johnson |Baird |Lowers |Neutral | $33.00|$37.00 | |William Plovanic |Canaccord Genuity |Maintains |Buy | $63.00|$63.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tandem Diabetes Care. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Tandem Diabetes Care compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Tandem Diabetes Care's stock. This examination reveals shifts in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Tandem Diabetes Care's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Tandem Diabetes Care analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Unveiling the Story Behind Tandem Diabetes Care
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Tandem Diabetes Care's Economic Impact: An Analysis
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Tandem Diabetes Care showcased positive performance, achieving a revenue growth rate of 43.62% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Tandem Diabetes Care's net margin excels beyond industry benchmarks, reaching 0.27%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.3%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Tandem Diabetes Care's ROA stands out, surpassing industry averages. With an impressive ROA of 0.08%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Tandem Diabetes Care's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.8, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
How Are Analyst Ratings Determined?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.